KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.

Remo Panaccione, Miguel Regueiro, Scott D Lee, Raja Atreya, Gitte Pedersen, Efrat Broide, Cristina Rodriguez, Adriaan A van Bodegraven, Elena Dubcenco, Ana P Lacerda, Tian Feng, Ziqian Geng, Tao Wang, Stijn van Haaren, Samuel I Anyanwu, Julian Panés

Clin Gastroenterol Hepatol 24(3) 772-783

PMID40738276
PMCID-
DOI10.1016/j.cgh.2025.07.028
发表日期2025-07-30
入排依据:The study is a Phase III randomized trial of a drug (upadacitinib) in Crohn's disease (non-oncology). The primary efficacy endpoints are CDAI clinical remission and endoscopic response at week 52, which are not time-to-event endpoints (e.g., OS, PFS). No Kaplan-Meier curves or hazard ratios for a time-to-event outcome are reported.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND & AIMS: Upadacitinib, an oral, reversible Janus kinase inhibitor, demonstrated efficacy and safety in patients with Crohn's disease in 2 phase III induction trials (U-EXCEL and U-EXCEED) and in a primary analysis of the first 502 patients entering the subsequent maintenance trial (U-ENDURE). Here, we present the overall results of the entire population of U-ENDURE (N = 673). METHODS: Clinical responders to 12 weeks of upadacitinib 45 mg once daily (QD) induction were randomized (1:1:1) to receive upadacitinib 15 mg QD (n = 221), upadacitinib 30 mg QD (n = 229), or placebo (n = 223) as maintenance therapy for 52 weeks. Coprimary endpoints were Crohn's Disease Activity Index (CDAI) clinical remission and endoscopic response at week 52. Safety was assessed through week 52. RESULTS: At week 52, more upadacitinib-treated vs placebo patients achieved CDAI clinical remission (upadacitinib 15 mg, 36.2% and upadacitinib 30 mg, 51.5% vs placebo, 15.2%). The rates of endoscopic response were 27.3% for upadacitinib 15 mg and 40.7% for upadacitinib 30 mg vs 7.2% for placebo. Exposure-adjusted event rates for treatment-emergent adverse events were numerically lower with upadacitinib 15 mg and 30 mg vs placebo (351.3 and 324.5 per 100 patient-years, respectively, vs 462.8 per 100 patient-years) except for COVID-19 and adverse events leading to early discontinuation of study treatment. No deaths, active tuberculosis, lymphoma, nonmelanoma skin cancer, adjudicated major cardiovascular adverse events, or venous thromboembolic events were reported from any treatment group. Herpes zoster infections occurred more frequently in the upadacitinib groups compared with placebo; all were nonserious, and most involved a single dermatome. CONCLUSIONS: Consistent with the primary analysis, upadacitinib was more efficacious than placebo in achieving clinical and endoscopic endpoints in patients with Crohn's disease. The safety profile remained consistent with no new safety signals. CLINICALTRIALS: gov Number: NCT03345823.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。